After Cancer Remission: Tracking Minimal Residual Disease and Relapse
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 November 2026 | Viewed by 79
Special Issue Editors
Interests: cancer; immunotherapy; lung cancer; treatment; vaccine
Special Issues, Collections and Topics in MDPI journals
Interests: lung cancer; biomarkers; immunotherapy; targeted therapy; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite significant advances in cancer therapy, disease recurrence remains a key challenge in oncology. The existing follow-up strategies can inform treatment decisions only when radiologically and/or clinically measurable disease is present, which requires substantial numbers of cancer cells and increased tumor burden. But a high disease burden increases the likelihood of genetic diversity as more cancer cells with clonal heterogeneity accumulate over time. The early and precise detection of minimal residual disease (MRD)—the small number of persisting malignant cells undetectable by conventional methods—can be proven crucial for improving patient outcomes.
This Special Issue of Cancers, titled “After Cancer Remission: Tracking Minimal Residual Disease and Relapse”, aims to highlight the latest research and technological innovations in this evolving field. We welcome original research articles, biomarker studies, methodological and computational tools, and comprehensive reviews focusing on MRD detection, molecular monitoring, and relapse prediction across hematologic and solid tumors.
Topics of interest include liquid biopsy and circulating tumor DNA (ctDNA) approaches, multi-omics profiling, single-cell analyses, imaging-based surveillance, and translational strategies linking MRD dynamics to clinical decision-making. By bringing together multidisciplinary perspectives, this Special Issue seeks to advance our understanding of post-remission disease biology and foster the development of personalized monitoring strategies to prevent and preempt cancer relapse.
Dr. Andriani Charpidou MD, PhD, FCCP. Associate Professor of Medical Oncology at the Medical School of National and Kapodistrian University of Athens. Dr. Andriani Charpidou graduated from the Medical School of the University of Patras in Greece and completed her training in Pulmonology and Bronchoscopy in 2002. She completed her thesis on Thoracic Oncology with distinction at the Medical School of NKUA in 2010. She had special training in Clinical Trials at the Vienna School of Clinical Research in 2007. Since then, she has been the Chief Head of the Clinical Trials Bureau at the 3rd Department of Internal Medicine of the National and Kapodistrian University of Athens Medical School. She is a member of the organizing and educational committee of two postgraduate courses on Thoracic Oncology and Drug Development at the NKUA Medical School of Athens. She has been the elected chair of the Lung Cancer Group of the Thoracic Assembly (11.1) of the European Respiratory Society since 2024. Her special interests are clinical trials in thoracic oncology and translational research in cancer.
Dr. Andriani Charpidou
Dr. Ioannis P. Trontzas
Dr. Emmanouil Panagiotou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- minimal residual disease (MRD)
- cancer relapse
- liquid biopsy
- circulating tumor DNA (ctDNA)
- biomarkers
- molecular monitoring
- post-remission surveillance
- translational oncology
- multi-omics
- personalized cancer care
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
